Puma Biotechnology, Inc. (PBYI)
Develops cancer drugs that target HER2-positive and other breast cancers.
$7.97-0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+159.6%
The outlook
PBYI is trading near its 52-week highs and above both its 50- and 200-day moving averages, reflecting strong near-term momentum. However, analyst price targets sit roughly 37% below the current price, suggesting a notable disconnect between current valuation and consensus expectations. The stock carries a trailing P/E of 16.6 amid this mixed technical-to-fundamental picture.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range86% of the way from its 52-week low to high
Price targetAvg target -37% vs current price
Market cap
$405.7M
52-wk high
$8.75
52-wk low
$3.03
50-day avg
$7.60
200-day avg
$6.54
Trailing P/E
16.6